Hepatitis News and Research

RSS
Medical aid workers should take pre-travel precautions to prevent disease transmission

Medical aid workers should take pre-travel precautions to prevent disease transmission

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

New lab-on-a-chip technology detects protein in blood less than 30 minutes

New lab-on-a-chip technology detects protein in blood less than 30 minutes

FDA, EMA accept boceprevir for expedited review

FDA, EMA accept boceprevir for expedited review

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Scientists identify prognostic biomarker to treat patients with HCV

Scientists identify prognostic biomarker to treat patients with HCV

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Anadys begins ANA598 Phase IIb study for hepatitis C

Anadys begins ANA598 Phase IIb study for hepatitis C

Hepatitis A scare at Long Island church

Hepatitis A scare at Long Island church

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Gene variant linked to liver cirrhosis in Caucasians

Gene variant linked to liver cirrhosis in Caucasians

Gene variation linked to liver cirrhosis in alcoholic caucasians

Gene variation linked to liver cirrhosis in alcoholic caucasians

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Researchers introduce new class of drugs for HCV patients

Researchers introduce new class of drugs for HCV patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.